3D Breast Tomosynthesis Better at Detecting Cancer than 2D Mammography
Lower recall rates, more cancer detection were seen with 3D digital breast tomosynthesis, compared with 2D digital mammography.
Mammography screening with 3D digital breast tomosynthesis (DBT) yields lower recall rates and increased cancer detection, compared with 2D digital mammography (DM), according to a study published in the American Journal of Roentgenology.
Researchers from Fairfax, Va., Bethesda, Md. and Israel assessed the clinical performance of combined 2D-3D DBT compared with 2D DM alone for screening mammography in a community-based radiology practice. The study period ran from August 2011 to November 2012. Fourteen radiologists compared the screening mammographies - 23,149 patients with 3D DBT versus 54,684 patients with 2D DM.
The results showed better results with 3D DBT over 2D DM:
• 3D DBT had a 16.1 percent lower recall rate than did 2D DM
• Overall cancer detection rate was 28.5 percent greater for 3D DBT (6.3 per 1,000 compared with 4.9 per 1,000 for 2D DM)
• Invasive cancer detection was 43.8 percent higher for 3D DBT (4.6 per 1,000 compared with 3.2 per 1,000 with 2D DM)
• Positive predictive value for recalls from screening was 53.3 percent greater for 3D DBT (4.6 percent) compared with 2D DM (3.0 percent)
• There was no significant difference in the positive predictive value for biopsy for 3D DBT versus 2D DM (22.8 percent and 23.8 percent, respectively)
“We observed a significant increase in the detection rate for cancer overall and an even greater increase in the detection rate for invasive cancer,” coauthor Julianne Greenberg said in a release. “Our results may be a bellwether for the impact of tomosynthesis on population-based breast cancer screening.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 2
July 23rd 2025In the second part of a multi-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, discuss key sequences for abbreviated breast MRI and how it stacks up to other breast cancer screening modalities.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
